Management strategies for severe Pseudomonas aeruginosa infections

• Published in: Current opinion in infectious diseases Vol. 36; no. 6; p. 585
• Main Authors: Do Rego, Hermann, Timsit, Jean-François
• Format: Journal Article
• Language: English
• Published: United States 01.12.2023
• Subjects: Anti-Bacterial Agents - therapeutic use; Aztreonam - therapeutic use; Humans; Pseudomonas Infections - drug therapy
• ISSN: 1473-6527
• DOI: 10.1097/QCO.0000000000000981

This review focuses on the management of severe Pseudomonas aeruginosa infections in critically ill patients. Pseudomonas aeruginosa is the most common pathogen in intensive care; the main related infections are nosocomial pneumonias, then bloodstream infections. Antimicrobial resistance is common; despite new antibiotics, it is associated with increased mortality, and can lead to a therapeutic deadlock. Carbapenem resistance in difficult-to-treat P. aeruginosa (DTR-PA) strains is primarily mediated by loss or reduction of the OprD porin, overexpression of the cephalosporinase AmpC, and/or overexpression of efflux pumps. However, the role of carbapenemases, particularly metallo-β-lactamases, has become more important. Ceftolozane-tazobactam, ceftazidime-avibactam and imipenem-relebactam are useful against DTR phenotypes (noncarbapenemase producers). Other new agents, such as aztreonam-ceftazidime-avibactam or cefiderocol, or colistin, might be effective for carbapenemase producers. Regarding nonantibiotic agents, only phages might be considered, pending further clinical trials. Combination therapy does not reduce mortality, but may be necessary for empirical treatment. Short-term treatment of severe P. aeruginosa infections should be preferred when it is expected that the clinical situation resolves rapidly.